Rising Rates of Hormone-Responsive Cancers
In the region, hormone-responsive cancers are rising sharply as population growth, urbanization, and lifestyle transitions converge with improved cancer awareness and screening. Breast cancer is the most prevalent malignancy among women across Indonesia, Thailand, Malaysia, Vietnam, and the Philippines, with a substantial proportion classified as estrogen or progesterone receptor–positive. Prostate cancer is increasingly diagnosed in men, particularly in Singapore, Malaysia, and Thailand, reflecting both aging populations and wider use of PSA testing in urban centers. While incidence rates vary, earlier detection and expanding survivorship are driving a steady increase in hormone therapy demand.
Rising obesity, physical inactivity, and adoption of Westernized diets in urban areas elevate estrogen-mediated breast cancer risk, while later age at childbirth and reduced breastfeeding duration are additional factors. In Singapore and Malaysia, national registries indicate that a growing fraction of breast cancer cases are hormone receptor–positive, underscoring the expanding need for endocrine treatment. Male populations are increasingly diagnosed with early-stage prostate cancer, increasing the pool of patients eligible for androgen-deprivation therapy.
Healthcare infrastructure across ASEAN shapes how hormone therapy is deployed. Advanced centers in Singapore, Thailand, and Malaysia are equipped to deliver oral and injectable endocrine therapies, while emerging economies such as Indonesia and the Philippines rely on centralized cancer centers for distribution. National cancer control programs are standardizing hormone therapy protocols, with essential medicines lists supporting access to tamoxifen, aromatase inhibitors, and LHRH analogs. As awareness and early diagnosis improve, long-term management with hormone therapy is expected to become an integral part of oncology care across the region.
Increasing Use of Combination Regimens
Combination therapy involving hormone agents is gaining momentum in ASEAN, particularly in middle- and high-income countries. In hormone receptor–positive breast cancer, combinations of aromatase inhibitors or fulvestrant with CDK4/6 inhibitors or mTOR inhibitors are increasingly adopted in Singapore, Malaysia, and Thailand, supported by public-private reimbursement schemes and guideline endorsements. These regimens allow earlier intervention in advanced disease, increasing treatment duration and per-patient consumption of endocrine agents.
Prostate cancer treatment is evolving toward combination approaches. Androgen-deprivation therapy paired with next-generation androgen receptor inhibitors or chemotherapeutic agents is gradually being introduced in Singapore, Malaysia, and urban hospitals in Thailand. While adoption is uneven in lower-resource settings, sequential hormone strategies are utilized to extend disease control. These combination regimens enhance the role of endocrine therapy as the backbone of multimodal management and create new demand opportunities for oral and injectable formulations.
Policy support, regional partnerships, and clinical capacity building are accelerating combination therapy uptake. Health technology assessments in Singapore and Thailand recognize progression-free survival and patient-reported outcomes, facilitating coverage for advanced regimens. Cross-country training initiatives and regional oncology networks promote adherence to international guidelines, while pharmaceutical access programs improve the availability of newer agents in emerging ASEAN markets. As precision medicine and guideline-driven therapy expand, combination hormone regimens are positioned to drive sustained growth for the ASEAN cancer hormone therapy market.
